Table 1: Numbers of benign (ben.) and malignant (mal.) images by DS and incidence rate in DSsDS	# ben. images	# mal. images	pmal inDS(S1,Ma)	13341	7258	0.3523(S1 , Mb)	527	408	0.4364(S2, Ma)	21871	160	0.0073(S2, Mb)	19040	146	0.0076(S3, Ma)	14192	1106	0.0723(S3, Mb)	46006	2059	0.0428(S4, Mc)	4387	28	0.0063(S4, Md)	19740	133	0.0067(S5, Mc)	38951	131	0.0034Cross-validation scheme For each experiment, the learning set is divided into training and val-idation data using a source-wise and patient-wise split: 80% (resp. 20%) of the patients of eachsource are used for training (resp. validation). Furthermore, the split is made such that the ratio ofmalignant / benign patients is similar for the validation and the training sets.
Table 2: Performances of DNNs on (S3, Ma).
Table 3: Performances on the data-segment (S3 , Ma) and (S3, Mb).
Table 4: Benchmark on 2 unknown manufacturers from the 3 DSs: (S4, Mc), (S4, Md), (S5, Mc).
Table 5: Additional statistics about DSs countries and number of images for each type of view. CCstands for Cranio-Caudal, MLO for Medio-Lateral Oblique, other for any other views.
Table 6: Malignant lesions types over the different DSsSegment Source Manufacturer Status Lesion type# images(S1,Ma)(S1,Ma)(S1,Ma)(S1,Mb)(S1 , Mb)(S1,Mb)(S2, Ma)(S2, Ma)(S2, Ma)(S2, Mb)(S2, Mb)(S2, Mb)(S3, Ma)(S3, Ma)(S3, Ma)(S3, Mb)(S3, Mb)
Table 7: Average age (mean Â± std) for patients in the different training and testing DSsSegment Source Manufacturer Status Age in years(S1,Ma)(S1,Ma)(S1,Mb)(S1,Mb)aabbMMMM1111SSSS(S2, Ma)(S2, Ma)(S2, Mb)(S2, Mb)2222SSSS(S3, Ma)(S3, Ma)(S3, Mb)(S3, Mb)
Table 8: Numbers of annotated lesions of each label. The corresponding numbers of annotated images are provided as well.			Segment	Label	# patches	# images(S1,Ma)	benign calcification	1611	1162(S1,Ma)	benign soft tissue lesion	4287	2252(S1,Ma)	healthy tissue	2597	1773(S1,Ma)	malignant calcification	2629	2254(S1,Ma)	malignant soft tissue lesion	5747	5187patients of each source are used for training (resp. validation). Furthermore, the split is made suchthat the ratio of malignant / benign patients is similar for the validation and the training sets.
